The stock of Milestone Pharmaceuticals Inc (MIST) has seen a 16.48% increase in the past week, with a 29.51% gain in the past month, and a -12.51% decrease in the past quarter. The volatility ratio for the week is 5.73%, and the volatility levels for the past 30 days are at 5.89% for MIST. The simple moving average for the last 20 days is 12.75% for MIST’s stock, with a simple moving average of 18.32% for the last 200 days.
Is It Worth Investing in Milestone Pharmaceuticals Inc (NASDAQ: MIST) Right Now?
The 36-month beta value for MIST is at 0.95. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for MIST is 52.90M, and currently, shorts hold a 3.80% of that float. The average trading volume for MIST on June 27, 2025 was 1.93M shares.
MIST) stock’s latest price update
Milestone Pharmaceuticals Inc (NASDAQ: MIST)’s stock price has soared by 1.47 in relation to previous closing price of 1.94. Nevertheless, the company has seen a gain of 16.48% in its stock price over the last five trading days. globenewswire.com reported 2025-06-16 that MONTREAL and CHARLOTTE, N.C., June 16, 2025 (GLOBE NEWSWIRE) — Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced submission of its response to the U.S. Food and Drug Administration (FDA)’s Complete Response Letter (CRL) regarding its New Drug Application (NDA) for CARDAMYST™ (etripamil) nasal spray, a prescription medication in development for the conversion of acute episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
Analysts’ Opinion of MIST
Many brokerage firms have already submitted their reports for MIST stocks, with H.C. Wainwright repeating the rating for MIST by listing it as a “Buy.” The predicted price for MIST in the upcoming period, according to H.C. Wainwright is $5 based on the research report published on June 05, 2025 of the current year 2025.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see MIST reach a price target of $9. The rating they have provided for MIST stocks is “Buy” according to the report published on August 22nd, 2024.
Jefferies gave a rating of “Hold” to MIST, setting the target price at $4 in the report published on June 20th of the previous year.
MIST Trading at 35.60% from the 50-Day Moving Average
After a stumble in the market that brought MIST to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.42% of loss for the given period.
Stock Fundamentals for MIST
The total capital return value is set at -1.07. Equity return is now at value -307.27, with -65.78 for asset returns.
Based on Milestone Pharmaceuticals Inc (MIST), the company’s capital structure generated 1.12 points at debt to capital in total, while cash flow to debt ratio is standing at -0.61. The debt to equity ratio resting at -9.08. The interest coverage ratio of the stock is -29.4.
Currently, EBITDA for the company is -42.1 million with net debt to EBITDA at -0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.67.
Conclusion
In conclusion, Milestone Pharmaceuticals Inc (MIST) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
